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ABSTRACT 
 
A CROSS-SECTIONAL STUDY OF PHTHALATE EXPOSURE AND 
INFLAMMATION BIOMARKER LEVELS AMONG POSTMENOPAUSAL WOMEN 
MAY 2020 
AVERY TRIM, B.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed By: Dr. Katherine Reeves 
Phthalates are industrial chemicals added to plastics found in products such as 
children’s toys, cosmetics, and household items, and some laboratory studies suggest 
phthalates may increase levels of inflammation. Chronic inflammation is associated with 
many chronic health conditions, such as diabetes and rheumatoid arthritis. Although 
research is limited, recent studies suggest a strong positive relationship between mono-
butyl phthalate (MBP), mono-isobutyl phthalate (MiBP), and monocarboxynonyl 
phthalate (MCNP) and c-reactive protein (CRP), as well as monoethyl phthalate (MEP) 
and mono-3-carboxypropyl phthalate (MCPP) and interleukin-6 (IL-6). Additionally, this 
relationship has not been examined among postmenopausal women, a population that is 
at higher risk of developing chronic health conditions. Our aim was to examine the 
association between urinary phthalate biomarkers and inflammation biomarkers among 
postmenopausal women using baseline data from a subset of participants of the Women’s 
Health Initiative (WHI) (n=443). Phthalate exposure was assessed using phthalate 
biomarkers (i.e. phthalate metabolites or their molar sum) from urine samples collected at 
WHI clinical centers from 1993-1998. We measured 13 phthalate metabolites: MEP, 
MBP, mono-hydroxybutyl phthalate (MHBP), MiBP, mono-hydroxyisobutyl phthalate 
 iv 
(MHiBP), monobenzyl phthalate (MBzP), MCPP, mono (2-ethylhexyl) phthalate 
(MEHP), mono (2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono (2-ethyl-5-
oxohexyl) phthalate (MEOHP), mono (2-ethyl-5-carboxypentyl) phthalate (MECPP), 
mono-carboxyoctyl phthalate (MCOP), and MCNP. Serum and plasma inflammatory 
biomarker levels (i.e. CRP, IL-6) were measured in separate WHI ancillary studies, using 
blood samples collected at baseline. We used multivariable linear regression to analyze 
associations between each phthalate biomarker and inflammation biomarker, adjusting 
for important covariates. Phthalate biomarkers MCNP (Model 1: b = 0.523; Model 2: b = 
0.362) and MCOP (Model 1: b = 0.384; Model 2: b = 0.240) were positively associated 
with CRP. Additionally, MCNP (Model 1: b = 0.369; Model 2: b = 0.181) was positively 
associated with IL-6. Statistically significant associations were not observed among the 
remaining phthalate biomarkers. Our findings suggest that certain phthalates may be 
related to increasing levels of inflammation. 
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CHAPTER I 
INTRODUCTION 
Accumulating scientific evidence, especially in recent years, indicates a 
potentially harmful relationship between phthalates and inflammation. Phthalates are 
man-made chemicals added to plastics, and can be found in many everyday household, 
personal care, medical, and child products.1 Detectable concentrations have been 
observed among the majority of the U.S. population in varying amounts.2 Inflammation is 
a response to the presence of unknown substances within the body and is a natural 
defense mechanism that typically occurs in acute phases.3 However, chronic 
inflammation, which often goes unresolved,3 is associated with rheumatoid arthritis4, 
Alzheimer’s disease,5 diabetes,5,6 cancer,5–7 cardiovascular disease6,8 and osteoporosis9, 
which are prevalent among postmenopausal women. 
Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is 
suggested as a potential mechanism behind the association between phthalates and 
inflammation. It is hypothesized that phthalate exposure leads to the activation of NF-kB, 
which signals the production of pro-inflammatory cytokines, such as interleukin-6 (IL-
6).10 NF-kB is also shown to stimulate production of c-reactive protein (CRP), however 
this process is suggested to occur through IL-6 and interleukin 1 beta (IL-1b).11 
Animal and cellular studies indicate that phthalate exposure can increase the 
production of pro-inflammatory cytokines, although this positive relationship is typically 
observed in higher phthalate metabolite concentrations.10,12–17 Prior epidemiological 
studies also indicate positive associations between phthalate metabolites MBP, MiBP, 
and MCNP and CRP, as well as MEP and MCPP and  IL-6.18–20 Directionality among 
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other phthalate metabolites is inconsistent and may be due to insufficient power from 
small sample sizes, or the use of a single phthalate urinary sample.18–21  
Prior research studies have not examined the relationship between phthalate 
metabolite concentrations and inflammation biomarker levels among postmenopausal 
women only. We investigated the associations between 13 phthalates metabolite and 2 
inflammation biomarkers using 1993-1998 baseline data from a subset of Women’s 
Health Initiative (WHI) participants. 
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CHAPTER II 
SUBJECTS AND METHODS 
 
A. Study population 
WHI is a large-scale national study evaluating potential strategies to prevent and 
minimize causes of morbidity and mortality among postmenopausal women.22 WHI 
conducted three clinical trials as well as a separate observational study from 1993-1998, 
enrolling a total of 161,808 postmenopausal women from 50-79 years old.23,24 Written 
informed consent was provided upon enrollment.24 In addition, WHI conducted a bone 
density substudy at three clinical sites, which included 11,020 participants from any of 
the clinical trials or the observational study. Our nested case-control study selected breast 
cancer cases and 2:1 matched controls from among WHI bone density substudy 
participants.23,25 A number of ancillary studies also occurred throughout the WHI study 
and measured inflammatory biomarkers on selected participants. Our cross-sectional 
study included selected participants from the nested-case control study with inflammatory 
biomarker values measured at baseline from overlapping ancillary studies (n=443). 
Participants were excluded if they 1) were missing baseline covariate information, and 2) 
had results measured using unreliable assays (i.e. those with high CV). Figure 1 shows 
the study population ascertainment for this analysis. 
 
B. Phthalate exposure assessment 
Phthalate exposure was assessed using biomarkers (i.e. urinary phthalate metabolites). 
First morning void urinary samples were conducted by participants at home and 
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refrigerated until their baseline visit at a WHI clinical center. During this visit samples 
were acquired and frozen by trained personnel until they were ready for shipment to 
McKesson Bioservices, where they were stored at -80°C. Participant samples used for the 
WHI nested-case control study were taken from McKesson Bioservices and sent to the 
CDC for processing and analysis. Urine samples were analyzed for 13 phthalate 
metabolites (MEP, MBP, MHBP, MiBP, MHiBP, MBzP, MCPP, MEHP, MEHHP, 
MEOHP, MECPP, MCOP, and MCNP) using enzymatic deconjugation of the 
glucuronidated analytes, followed by assessment of exposure levels using on-line solid 
phase extraction and high performance liquid chromatography-electrospray ionization-
tandem mass spectrometry. Each phthalate metabolite (or their molar sum) were 
considered as continuous variables in the analyses.  
 Phthalate exposure was assessed using an objective measure (i.e. urine sample). In 
addition, laboratory workers were not privy to any information that could identify 
participants based on their urinary sample, such as disease status. Coefficient of variation 
(CV), which uses blinded duplicate samples to examine potential differences in lab 
values, was used on 10% of phthalate metabolite samples to assess validity. CVs were 
5.4% for MBP, 6.1% for MBzP, 4.7% for MCNP, 6.3% for MCOP, 5.8% for MCPP, 
4.3% for MECPP, 5.4% for MEHHP, 19.5% for MEHP, 6.0% for MEOHP, 3.1% for 
MEP, 9.0% for MHBP, 21.9% for MHiBP, and 10.3% for MiBP.23 Phthalate metabolite 
concentrations below the limit of detection (LOD) were given a value equal to LOD / 
Ö2.23 Five phthalate metabolites had samples whose concentrations were below the LOD 
(MBP = 0.07%, MEHP = 0.63%, MHBP = 0.43%, MHiBP = 1.56%, MiBP = 0.46%.23 
All samples from the eight other phthalate metabolites were above the LOD.  
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C. Inflammation biomarker assessment 
 Blood samples were collected at WHI clinical centers during the first screening 
visit, prior to which participants were required to fast for at least 12 hours. Participants 
were also asked to refrain from smoking, taking aspirin or nonsteroidal anti-inflammatory 
drugs (NSAIDs), or partaking in strenuous physical activity prior to their visit. To 
separate plasma (ethylenediaminetetraacetic acid (EDTA) and citrate) and serum from the 
blood, samples were left to clot at 4°C for approximately one hour and then centrifuged 
for 10 minutes. Separated serum and plasma were then placed into multiple smaller vials 
and frozen at -70°C for 2 hours until they were ready to be shipped to McKesson 
Bioservices for permanent storage at -80°C. Samples were then shipped from McKesson 
Bioservices to a laboratory for analysis. Among the 22 ancillary studies included in our 
final sample, inflammation biomarker levels were measured at approximately 10 different 
laboratories using around 6 different assay methods (Immulite Immunoasasy Analyzer, 
Enzyme Linked Immunosorbent Assay (ELISA), Quantikine High Sensitivity 
Immunoassay, Luminex Multiplex Cytokine Assay, Roche Modular P Chemistry 
Analyzer, Behring Nephelometer II Analyzer). Inflammation biomarkers were measured 
as continuous variables in our analyses.  
 An average CV percentage was calculated based on groupings by biomarker, 
sample type, testing method, and lab.26 Average CVs ranged from 1.9% to 9.2% among 
CRP values,27 and 4% to 42% among IL-6 values.27 The correlation coefficient, which 
measures the degree of association between blinded duplicate sample pairs, was 
calculated and averaged based on groupings by biomarker, sample type, testing method, 
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and lab.26 Average correlation coefficients ranged from 0.9-1.0 among CRP values and 
0.75-1.0 among IL-6 values.27  
 
D. Consolidation of inflammation biomarker results 
Some participants had multiple CRP and/or IL-6 results from various WHI ancillary 
studies. Among participants with more than one specimen type (i.e. citrate, serum, 
EDTA) per inflammation biomarker, a single result was selected based on the frequency 
of specimen types within the total sample. Random sampling was used in order to select 
one result per biomarker and participant. Additionally, to harmonize inflammation 
biomarker results across ancillary studies, predicted values of each inflammatory 
biomarker were calculated from linear regression models using strong predictors 
including age, smoking status, BMI, use of anti-inflammatory medication 48 hours prior 
to blood draw, ancillary study ID (i.e. assay method and lab), and storage time (i.e. the 
time between blood draw and assay). Predicted CRP levels equal to zero were given a 
value of 0.025 (ng/mL or pg in order to allow for log transformation of values.  
 
E. Covariate assessment 
 Sociodemographic and behavioral characteristics, as well as medical history were 
ascertained from a self-report questionnaire completed at first screening visit. Physical 
measurements (ex. Height, blood pressure) were taken at first screening visit. Current 
medication information was determined by collection of participant medications at first 
screening visit and later recording prescription information. We included age,18,21,28 
creatinine,18 race/ethnicity,18,20 socioeconomic status,21 smoking status,21 alcohol intake,21 
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and BMI18–21 as covariates based on prior epidemiological studies. Total physical activity 
was also included as a covariate, as prior literature indicates confounding between 
phthalate exposure and inflammation.23,29 
 
F. Statistical analysis 
Phthalate biomarkers (i.e. individual metabolites or their molar sums) and 
inflammation biomarkers were natural log transformed for data to follow a normal 
distribution. Demographic and behavioral characteristics of the study population were 
summarized by inflammation biomarker and compared to distributions in the nested case-
control study. T-tests or chi-square tests were used to examine potential differences in 
characteristics between participants sample sizes for each inflammation biomarker and 
the nested case-control study. Distributions (i.e. mean, standard deviation, range) of 
phthalate biomarker (creatinine-standardized) and inflammation biomarker levels were 
calculated. Pearson’s correlations were calculated to assess the level of dependence of 
each phthalate biomarker and inflammation biomarker.  
Two multivariable linear regression models were used to examine the relationship 
between each phthalate biomarker and inflammation biomarker. Covariates which 
produced at least a 10% change in inflammation biomarker level estimates were included 
in both models. Model 1 was adjusted for age, creatinine, socioeconomic status, alcohol 
intake, and smoking status as covariates. Model 2 was adjusted for covariates included 
Model 1 as well as BMI. Among most phthalate biomarkers, race/ethnicity and total 
physical activity had little impact on the estimated association with inflammation 
biomarkers (<10% change) in both models, and therefore were not included as covariates. 
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Our analyses included 443 participants (CRP, n=414; IL-6, n=177) who had complete 
data on covariates, exposure, and outcome. As a sensitivity analysis, we repeated our 
multivariable linear regression analyses using participants who were not identified as 
current NSAID users based on medication data collection at baseline. For all of our 
analyses, a p-value < 0.05 was considered statistically significant. 
Power calculations were based on a Type III F test within a multiple linear 
regression model. Among participants with CRP values (n=414), we had >80% power to 
explain 10-20% of variability (i.e. standard error) in values with 95% confidence, based 
on the inclusion of 6 predictors and use of continuous phthalate metabolites. Using the 
same criteria, we had >80% power among participants with IL-6 values (n=177). 
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CHAPTER III 
RESULTS 
 
 Table 2 describes the distribution of sociodemographic and behavioral 
characteristics of the study participants in this cross-sectional study by inflammation 
biomarker, in comparison to the distribution within the nested case-control study. 
Compared to participants within the nested case-control study, participants with CRP 
values were more likely to be non-white, non-drinkers, have a higher annual income and 
lower socioeconomic status. Similarly, participants with IL-6 values were more likely to 
be older, non-white, past-smokers, and consume less than 1 drink per week. 
 Table 3 describes the distribution of creatinine-standardized phthalate biomarker 
concentrations and inflammation biomarker levels among all study participants. MBzP, 
MCPP, MCOP and MCNP concentrations have similar values ranging from 0.007 µg/g to 
2.558 µg/g. SDEHP, SDBP, and SDiBP concentrations have similar values ranging from 
0.00003 µg/g to 0.083 µg/g. MEP concentrations range from 0.088 µg/g to 130 µg/g, 
with an average value of 3.8 µg/g. The distribution of CRP levels ranges from 0.025 
mg/L to 16.4 mg/L, with a mean of 14.9 mg/L and a standard deviation of 3.0 mg/L. IL-6 
levels range from 0.029 pg/mL to 11.2 pg/mL, with a mean of 2.9 pg/mL and a standard 
deviation of 2.0 pg/mL. 
Table 4 describes the relationship between each creatinine-standardized phthalate 
biomarker and inflammation biomarker using Pearson’s correlation. Overall, results 
indicate a weak, non-significant correlation between each phthalate biomarker and 
inflammation biomarker. However, we observed statistically significant, positive 
 10 
correlation between MCNP and IL-6 (r = 0.20, p = 0.01). 
 Multivariable linear regression models assessing the relationship between each 
creatinine-standardized phthalate biomarker and inflammation biomarker are shown in 
Tables 5 and 6. Coefficients represent the change in inflammatory biomarker per 10-unit 
change in the phthalate metabolite on the natural scale. Model 1 is adjusted for age, 
creatinine, alcohol intake, socioeconomic status, and smoking status. Model 2 is adjusted 
for covariates in Model 1 as well as BMI. We observed statistically significant, positive 
associations between MCNP and CRP in both models: Model 1 (b = 0.523; p = 0.0002), 
Model 2 (b = 0.362; p = 0.004). Similarly, we found a statistically significant positive 
association between MCNP and IL-6 in Model 1 (b = 0.369, p = 0.01), but not in Model 
2. We also observed a statistically significant positive association between MCOP and 
CRP in Model 1 (b = 0.384, p = 0.01) and a borderline significant positive association in 
Model 2 (b = 0.240, p = 0.05). Similar results were observed when restricting these 
analyses to participants not currently using NSAIDs (Tables 7 and 8). 
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CHAPTER IV 
DISCUSSION 
   
 Overall, we did not observe strong, statistically significant associations between 
urinary phthalate biomarkers and CRP or IL-6 in our sample of postmenopausal women 
from WHI. We found a significant positive association between MCNP and CRP when 
including and excluding BMI as a covariate, with comparable findings between MCOP 
and CRP. A similar trend is observed among participants not currently using NSAIDs, 
indicating that NSAID use does not affect the relationship between phthalates and 
inflammation. Ferguson et al. observed positive associations for MCNP, and positive and 
negative associations for MCOP.18,19 We also found a statistically significant, positive 
association between MCNP and IL-6 when excluding BMI as a covariate, which was 
attenuated and not statistically significant when including BMI as a covariate. Ferguson 
et al. 2014 found an increase in IL-6 levels in association with an interquartile range 
increase in MCNP (%Δ = 16.8, 95% CI: 2.69, 32.9, p=0.02) while adjusting for BMI.  
Our results suggest a positive association between MCNP and inflammation, as 
this relationship was observed among both inflammation biomarkers (CRP and IL-6). 
Although a statistically significant relationship was observed between MCOP and CRP, 
this was not observed with IL-6, which is potentially the result of reduced sample size 
and statistical power. Our results also show an attenuation in strength of the association 
between phthalate biomarkers and inflammation biomarker levels in models including 
BMI as a covariate, compared to models excluding BMI as a covariate. However, this 
trend is not consistent across all phthalate metabolites. A potential explanation for the 
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conflicting findings is the varying sources of phthalate exposure. Diet is a common 
source of phthalate exposure among the majority of individuals.1 DiNP, which 
metabolizes into MCOP can be found in food packaging,30 which often contain unhealthy 
food items. Although information is not readily available, as of March 2020 past federal 
regulations from the U.S Food & Drug Administration cite DiDP (i.e. MCNP) as a 
substance used in food packaging.31 Furthermore, obesity is an established risk factor for 
inflammation.6 As our sample population has an average BMI of 28 kg/m2 and a standard 
deviation of roughly 6 kg/m2, indicating an overweight population, it is possible that the 
attenuation in strength of association among some phthalates is the result of correctly 
adjusting for confounding due to BMI. It is also a possibility that the relationship 
between some phthalates and inflammation occurs indirectly through BMI. In this case, 
linear regression models excluding BMI as a covariate more accurately reflect the true 
association as compared to models including BMI as a covariate. The increased in 
strength of association among certain phthalate biomarkers may be the result of 
originating from an exposure source unrelated to BMI, such as indoor air or dust.1 This 
could produce an overestimation of the association between phthalate exposure and 
inflammation, as BMI is adjusted for unnecessarily. Our findings also suggest that 
NSAID does not confound the relationship between phthalate exposure and 
inflammation, as we observed similar associations among our restricted sample as 
compared to our full sample.  
 A potential explanation for differences in findings across studies is the sample 
population. A total of 5 prior epidemiological studies examined the relationship between 
individual urinary phthalate metabolites and inflammation biomarkers. Sample 
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populations include pregnant women and men and women of varying ages. Our study is 
the first to examine the relationship between phthalate exposure and inflammation 
biomarker levels among postmenopausal women only. It possible that certain populations 
are impacted differently by inflammation, resulting in conflicting results across studies. 
We excluded participants with missing exposure, outcome and covariates as well as 
participants with inflammatory biomarker values obtained from unreliable assays (i.e. 
those with high CV). The reduced sample size and lowered statistical power may have 
contributed to differences between our findings compared to those from prior studies.   
We observed null finding across all other phthalate metabolites, which differs 
from prior epidemiological studies. A potential explanation for these null associations 
could be differences in sample size and phthalate exposure assessment. Our study uses a 
single urine sample to assess phthalate exposure in comparison to prior studies which use 
up to 4 samples in a repeated cross-sectional study to measure change in phthalate 
exposure over time. Phthalates quickly pass through the body and reduce to half their 
original amount anywhere from 3 to 18 hours following exposure.32 As a result, a single 
urine sample may not accurately reflect participants long-term exposure. This can also 
create high within-person variation as phthalate metabolites concentrations can change 
daily, leading to nondifferential misclassification among participants in our sample. As a 
result, our observed association may be attenuated. Our sample sizes for CRP (n=414) 
and IL-6 (n=177) are generally smaller compared to the sample sizes of prior studies. The 
use of a single measurement as well as a small sample size increases the variability of 
values and decreases the power, therefore reducing the ability to observe an association.  
Our study is limited by the reliance on inflammatory biomarker levels that were 
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combined from multiple WHI ancillary studies. Inflammatory biomarker levels varied by 
specimen type, lab, assay method, and storage time, leading to differences in 
measurement among our sample. Additionally, as inflammation biomarker levels were 
selected based on availability from other studies, it is possible that by design, our sample 
population is different (i.e. sicker, older) from the WHI study population. To minimize 
potential measurement error, we used strong predictors of inflammation (i.e. age, 
smoking status, BMI, use of anti-inflammatory medication 48 hours prior to blood draw, 
study ID, and storage time) to estimate CRP and IL-6 values and standardize our results. 
Results from our prediction model were in line with our expectations regarding 
directionality (Table 1). However, we did not observe a statistically significant 
relationship between predictors age and anti-inflammatory medication use and CRP 
levels. We also did not observe a statistically significant relationship between predictors 
age, smoking status, and anti-inflammatory medication use and IL-6 levels. As a result, it 
is likely that some measurement error remains among our predicted CRP and IL-6 values. 
To understand the level of bias that may have occurred through sample selection, we 
compared the distribution of characteristics within our sample sizes for CRP (n=414) and 
IL-6 (n=177) values to participants within the nested case-control study (n=1,257). 
Although our samples differed by age, race/ethnicity, and SES index, the remaining 
characteristics were not statistically significantly different from the nested case-control 
sample.  
There are several strengths to our cross-sectional study. First, this is the first study 
to assess this association among postmenopausal women only. As this population is at 
higher risk for developing inflammation-related chronic conditions (diabetes, rheumatoid 
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arthritis, etc.), our findings could provide insight into the mechanism between phthalate 
exposure and inflammation and could lead to improvements in disease prevention. 
Second, although residual confounding is a potential concern in any study, we were able 
to adjust for a large number of confounders in our analyses. As a result, we were able to 
assess the potential impact of certain covariates on the relationship between urinary 
phthalate biomarkers and inflammation biomarker levels. Third, we expect our results to 
be generalizable to all postmenopausal women. Although the biological mechanism 
between phthalate exposure and inflammation is not established, we do not expect that 
mechanisms linking phthalate exposure to inflammation would vary by age, 
race/ethnicity, or geographic location.  
In conclusion, our study indicates an overall positive association between MCNP 
and inflammation biomarkers CRP and IL-6. Although the relationship between MCNP 
and IL-6 is borderline significant when including BMI as a confounder (p=0.05), it is 
possible that BMI is instead an intermediary step between phthalate exposure and 
inflammation. Further research should examine this relationship as it relates to BMI. 
Additionally, future studies should aim to use a larger sample size and include additional 
inflammation biomarkers (ex. TNF-a and IL-8). 
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APPENDIX 
SUPPLEMENTAL TABLES 
 
Table 1. Beta coefficients and 95% confidence intervals for predictors of 
inflammation and CRP and IL-6 levels  
  CRP IL-6 
  Beta (95% CI) p-value Beta (95% CI) p-value 
Age 0.02 (-0.05, 0.09) 0.56 
0.002 (-0.07, 
0.08) 0.95 
Smoking status         
Never smoked Reference -- Reference -- 
Past smoker 2.25 (1.32, 3.19) <0.0001b 0.44 (-0.49, 1.37) 0.93 
Current smoker 2.62 (0.76, 4.47) 0.005b 0.21 (-1.93, 2.35) 0.19 
BMI 0.45 (0.37, 0.53) <0.0001b 0.15 (0.07, 0.23) 0.0003b 
Anti-inflammatory 
medication usea         
No Reference -- Reference -- 
Yes -0.81 (-1.74, 0.11) 0.08 
-0.53 (-1.43, 
0.37) 0.25 
aanti-inflammatory medication use in the last 48-hours prior to blood draw 
bp<0.05 
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Clinical Trials and Observational Study
n = 161,808
Bone Density Substudy
n = 11,020
Nested Case-Control Study
n = 1,257
Final Sample
n = 443
Excluded (n=814)
• Missing CRP or IL-6 results 
or results measured using 
unreliable assays (n=798)
• Missing covariate information 
(n=16)
Figure 1. Study population ascertainment for the analysis of phthalate exposure and 
inflammation biomarker levels in postmenopausal women 
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CRP
N=266
IL-6
N=29
Both
N=148
Figure 2. Venn diagram of inflammation 
biomarker results among participants 
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Table 2. Distribution of sociodemographic and behavioral characteristics in the Women's 
Health Initiative Study (WHI); 1993-1998 
 CRP 
sample 
(n=414) 
p-valuea IL-6 
sample 
(n=177) 
p-
valuea 
Nested case 
control 
(n=1,257) 
Age, years; Mean(SD) 63.1(7.0) 0.10 64.0(6.5) 0.01b 62.9(6.9) 
Race/ethnicity; N(%)  <0.0001b  0.01b  
White 247(59.7)  133(75.1)  1,045(83.1) 
Non-white 167(40.3)  44(24.9)  212(16.9) 
Education level; N(%)  0.47  1.00  
Less than high school degree 121(29.5)  48(27.8)  345(27.6) 
Post high school/some college 155(37.8)  63(36.4)  456(36.5) 
College degree or higher 134(32.7)  62(35.8)  450(36.0) 
Income level, yearly; N(%)  0.06  0.39  
<35,000 214(54.6)  88(52.7)  585(49.1) 
>=35,000 178(45.4)  79(47.3)  606(50.9) 
SES index - inflation 
adjusted; Mean(SD) 
70.4(10.5) <0.0001b 72.5(10.0) 0.46 73.1(8.7) 
Alcohol intake; N(%)  0.05  0.61  
0 drinks per week 164(39.6)  60(33.9)  412(33.0) 
<1 drink per week 141(34.1)  68(38.4)  431(34.5) 
1-6 drinks per week 76(18.4)  35(19.8)  288(23.1) 
7+ drinks per week 33(8.0)  14(7.9)  117(9.4) 
Smoking status; N(%)  0.63  0.35  
Never smoked 241(58.2)  91(51.4)  698(56.4) 
Past smoker 144(34.8)  76(42.9)  461(37.3) 
Current smoker 29(7.0)  10(5.7)  78(6.3) 
Body mass index, kg/m2; 
Mean(SD) 
28.7(6.0) 0.06 28.2(5.6) 0.84 28.1(5.8) 
Physical activity level, MET 
hrs/week; Mean(SD) 
11.5(13.5) 0.52 12.1(13.3) 0.96 12.0(14.4) 
Current NSAID use; N(%)  0.82  0.35  
Yes 258(62.3)  105(59.3)  791(62.9) 
No 156(37.7)  72(40.7)  466(37.1) 
Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; SES, socioeconomic; MET, 
metabolic equivalent 
ap-values are for the comparison of CRP and IL-6 samples to the nested case-control sample 
bp<0.05      
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Table 3. Distribution of creatinine-standardized phthalate metabolite 
concentrations and inflammation biomarker levels in the Women's Health 
Initiative (WHI) Study (n=443); 1993-1998 
Phthalate 
metabolites  Mean SD Min 
25th 
percentile 
75th 
percentile Max 
DEHP, umol/ga 0.0033 0.0050 0.0002 0.0016 0.0038 0.0831 
DBP, umol/gb 0.0025 0.0029 0.0001 0.0010 0.0031 0.0359 
DiBP, umol/gc 0.0003 0.0004 0.00003 0.0001 0.0003 0.0046 
MEP, ug/g 3.758 12.566 0.088 0.544 2.588 130.046 
MBzP, ug/g 0.232 0.240 0.013 0.099 0.270 2.149 
MCPP, ug/g 0.061 0.087 0.007 0.028 0.062 1.152 
MCOP, ug/g 0.084 0.185 0.009 0.032 0.077 2.558 
MCNP, ug/g 0.059 0.136 0.007 0.023 0.056 2.372 
CRP (mg/L)d 4.885 2.995 0.025 2.836 6.652 16.415 
IL-6 (pg/mL)e 2.941 2.016 0.029 1.650 3.354 11.227 
asum of MEHP, MEHHP, MEOHP, and MECPP 
bsum of MBP and MHBP 
csum of MiBP and MHiBP 
dn=414 
en=177 
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Table 4. Pearson correlation table for creatinine-
standardized phthalate metabolite concentrations 
and inflammation biomarker levels in the Women's 
Health Initiative (WHI) Study; 1993-1998 
  
CRP  
(n=414) 
IL-6  
(n=177) 
  r p r p 
DEHPb 0.020 0.69 0.031 0.68 
DBPc -0.037 0.46 0.070 0.93 
DiBPd 0.009 0.86 0.019 0.81 
MEP 0.008 0.88 -0.017 0.83 
MBzP 0.023 0.64 -0.088 0.24 
MCPP 0.015 0.76 -0.028 0.72 
MCOP 0.039 0.43 0.082 0.28 
MCNP 0.080 0.12 0.202 0.007e 
aphthalate metabolite concentrations and 
inflammation biomarker levels were log-
transformed 
bsum of MEHP, MEHHP, MEOHP, and MECPP 
csum of MBP and MHBP 
dsum of MiBP and MHiBP 
ep<0.05 
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Table 5. Multiple linear regression and 95% confidence intervals for phthalate metabolite 
concentrations and CRP levels (n=414)a 
  Model 1b Model 2c 
  Beta (95% CI) p-value Beta (95% CI) p-value 
DEHPd 0.248 (-0.061, 0.557) 0.11 0.103 (-0.142, 0.348) 0.41 
DBPe -0.009 (-0.275, 0.256) 0.95 -0.071 (-0.280, 0.139) 0.51 
DiBPf 0.103 (-0.173, 0.380) 0.46 0.002 (-0.217, 0.221) 0.98 
MEP 0.040 (-0.164, 0.243) 0.70 0.010 (-0.151, 0.170) 0.91 
MBzP 0.110 (-0.164, 0.384) 0.43 -0.079 (-0.297, 0.139) 0.48 
MCPP 0.218 (-0.099, 0.534) 0.18 0.136 (-0.115, 0.386) 0.29 
MCOP 0.384 (0.076, 0.692) 0.01g 0.240 (-0.004, 0.485) 0.05 
MCNP 0.523 (0.276, 0.890) 0.0002g 0.362 (0.116, 0.607) 0.004g 
aphthalate metabolite concentrations and inflammation biomarker levels were log-
transformed. coefficients shown are based on a 10-unit change on the natural scale 
badjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status 
cadjusted for model 1 + BMI 
dsum of MEHP, MEHHP, MEOHP, and MECPP 
esum of MBP and MHBP 
fsum of MiBP and MHiBP 
gp<0.05 
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Table 6. Multiple linear regression and 95% confidence intervals for phthalate metabolite 
concentrations and IL-6 levels (n=177)a 
  Model 1b Model 2c 
  Beta (95% CI) p-value Beta (95% CI) p-value 
DEHPd 0.096 (-0.195, 0.387) 0.52 -0.044 (-0.291, 0202) 0.72 
DBPe 0.081 (-0.194, 0.356) 0.56 0.076 (-0.154, 0.307) 0.51 
DiBPf 0.137 (-0.142, 0.416) 0.34 0.069 (-0.166, 0.304) 0.56 
MEP 0.010 (-0.168, 0.189) 0.91 0.008 (-0.142, 0.157) 0.92 
MBzP -0.088 (-0.365, 0.190) 0.53 -0.150 (-0.382, 0.082) 0.20 
MCPP -0.048 (-0.359, 0.263) 0.76 -0.067 (-0.328, 0.194) 0.61 
MCOP 0.172 (-0.089, 0.433) 0.20 0.014 (-0.209, 0.237) 0.90 
MCNP 0.369 (0.081, 0.658) 0.01g 0.181 (-0.068, 0.431) 0.15 
aphthalate metabolite concentrations and inflammation biomarker levels were log-
transformed. coefficients shown are based on a 10-unit change on the natural scale 
badjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status 
cadjusted for model 1 + BMI 
dsum of MEHP, MEHHP, MEOHP, and MECPP 
esum of MBP and MHBP 
fsum of MiBP and MHiBP 
gp<0.05 
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Table 7. Multiple linear regression and 95% confidence intervals for phthalate metabolite 
concentrations and CRP levels (n=258) among participants not currently using NSAIDsa 
  Model 1b Model 2c 
  Beta (95% CI) p-value Beta (95% CI) p-value 
DEHPd 0.376 (0.005, 0.747) 0.047g 0.236 (-0.058, 0.530) 0.12 
DBPe -0.033 (-0.372, 0.306) 0.85 -0.050 (-0.317, 0.216) 0.71 
DiBPf 0.034 (-0.298, 0.367) 0.84 0.045 (-0.217, 0.307) 0.74 
MEP 0.092 (-0.168, 0.352) 0.49 0.061 (-0.144, 0.266) 0.56 
MBzP 0.282 (-0.065, 0.629) 0.11 0.10 (-0.176, 0.376) 0.48 
MCPP 0.263 (-0.111, 0.637) 0.17 0.181 (-0.114, 0.476) 0.23 
MCOP 0.553 (0.171, 0.934) 0.0005g 0.382 (0.079, 0.685) 0.01g 
MCNP 0.584 (0.210, 0.957) 0.002g 0.345 (0.046, 0.644) 0.02g 
aphthalate metabolite concentrations and inflammation biomarker levels were log-
transformed. coefficients shown are based on a 10-unit change on the natural scale 
badjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status 
cadjusted for model 1 + BMI 
dsum of MEHP, MEHHP, MEOHP, and MECPP 
esum of MBP and MHBP 
fsum of MiBP and MHiBP 
gp<0.05 
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Table 8. Multiple linear regression and 95% confidence intervals for phthalate metabolite 
concentrations and IL-6 levels (n=105) among participants not currently using NSAIDsa 
  Model 1b Model 2c 
  Beta (95% CI) p-value Beta (95% CI) p-value 
DEHPd 0.084 (-0.261, 0.429) 0.63 -0.069 (-0.363, 0.225) 0.64 
DBPe -0.090 (-0.447, 0.267) 0.62 0.009 (-0.294, 0.312) 0.95 
DiBPf 0.224 (-0.145, 0.593) 0.23 0.130 (-0.183, 0.443) 0.41 
MEP 0.096 (-0.152, 0.344) 0.44 0.122 (-0.086, 0.330) 0.25 
MBzP 0.050 (-0.321, 0.421) 0.79 -0.048 (-0.362, 0.265) 0.76 
MCPP -0.075 (-0.465, 0.315) 0.70 -0.045 (-0.373, 0.283) 0.78 
MCOP 0.223 (-0.125, 0.570) 0.21 0.006 (-0.297, 0.309) 0.97 
MCNP 0.401 (0.017, 0.784) 0.04g 0.193 (-0.142, 0.527) 0.26 
aphthalate metabolite concentrations and inflammation biomarker levels were log-
transformed. coefficients shown are based on a 10-unit change on the natural scale 
badjusted for age, creatinine, alcohol intake, socioeconomic status, and smoking status 
cadjusted for model 1 + BMI 
dsum of MEHP, MEHHP, MEOHP, and MECPP 
esum of MBP and MHBP 
fsum of MiBP and MHiBP 
gp<0.05 
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